



TESARO, Inc.
Investor Relations Department
1000 Winter St., Ste. 3300
Waltham, MA 02451
United States

[Visit IR website](#) 
[Sign-up for Email alerts](#) 

NASDAQ: TSRO

Last Trade: 118.06

Trade Time: 2:58 PM ET
9/25/2017

Change: -0.98  (-0.823%)

Day Range 117.03 - 119.48

52-Week Range 96.52 - 192.94


Volume 351,165

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Founded in 2010, TESARO is a publicly-traded oncology focused company dedicated to improving the lives of cancer patients. The Company intends to leverage the experience and competencies of its management team to identify, acquire and develop promising drug candidates. Upon successful development and regulatory approval of any of our product candidates, TESARO intends to make them available to cancer patients in North America, Europe and China through its own commercialization efforts and to establish a network of licensees and distributors in other geographic areas. For more information... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

9/15/2017

[TESARO Receives Positive CHMP Opinion for ZEJULA®](#)

9/11/2017

[TESARO Summarizes ZEJULA and TSR-042 Data Presented at the 2017 ESMO Annual Meeting](#)

8/25/2017

[TESARO Announces Nine Data Presentations at the 2017 European Society for Medical Oncology \(ESMO\) Annual Meeting](#)

8/23/2017

[TESARO Announces Participation at Four Investor Conferences](#)

8/08/2017

[TESARO Announces Second-Quarter 2017 Operating Results](#)

Upcoming Events [\[View all \]](#)

9/28/2017 8:00 AM ET

[Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology](#)

Financials [\[View all \]](#)

2/28/2017

[Annual Report \(10-K\)](#)

4/07/2017

[Proxy Statement \(DEF 14A\)](#)

8/08/2017

[Quarterly Report \(10-Q\)](#)

5/09/2017

[Quarterly Report \(10-Q\)](#)

11/04/2016

[Quarterly Report \(10-Q\)](#)